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athological phenotypes in inclusion
body myopathy (IBM) associated
with Paget disease of the bone (PDB),
frontotemporal dementia (FTD) and
amyotrophic lateral sclerosis (ALS)
(IBMPFD/ALS)
include
defective
autophagosome and endosome maturation that result in vacuolation, weakness
and muscle atrophy. The link between
autophagy and IBMPFD/ALS pathobiology has been poorly understood. We
examined the AKT-FOXO3 and MTOR
pathways to characterize the regulation
of autophagy in IBMPFD/ALS mouse
muscle. We identified a defect in MTOR
signaling that results in enhanced
autophagosome biogenesis. Modulating
MTOR signaling may therefore be a viable therapeutic target in IBMPFD/ALS.
Mutations in valosin containing protein
(VCP) cause IBM associated with PDB,
FTD and ALS. Prominent pathological
phenotypes in VCP-associated disease
include muscle weakness, which manifests
in ~90% of patients. Moreover, vacuoles in
IBMPFD/ALS patient skeletal muscle contain autophagic and endocytic markers,
such as SQSTM1/p62, LC3 and LAMP2.
That autophagosome and endosome maturation is disrupted in IBMPFD/ALS is a
serious concern because autophagic degradation is critical for cellular homeostasis.
We reasoned that defects in regulatory
components, such as MTOR, which control autophagy, may contribute to pathogenesis of IBMPFD/ALS. The R155H
mutation is the most common IBMPFD
mutation, and the majority of patients
with IBMPFD/ALS bear VCP mutations
in this residue. We made use of a mouse
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model that expresses the VCP-R155H
mutation (VCP-RH) and recapitulates
the myopathy component of IBMPFD/
ALS to characterize the regulation of the
MTOR-autophagy pathway with respect
to IBMPFD/ALS pathogenesis.
In an effort to further understand
autophagic dysfunction in IBMPFD/
ALS, we examined the AKT-FOXO3 and
MTOR pathways, which regulate autophagy in skeletal muscle, and found that
basal levels of phosphorylated AKTSer473
and phosphorylated FOXO3Ser253 are normal in VCP-RH mice when compared
with control mice and mice overexpressing
the wild-type VCP transgene (VCP-WT
mice). This observation was further confirmed by expression of downstream targets of FOXO3, which were found to be
unchanged. However, when compared
with control and VCP-WT mice, the levels
of phosphorylated forms of direct targets
of MTOR are reduced in two different
VCP-RH mouse lines. These findings suggest that MTOR signaling independent of
AKT is defective in VCP-RH-expressing
mouse muscle. Consistent with the fact
that the MTOR direct targets EIF4EBP1
and RPS6KB1/p70S6 kinase 1 regulate
protein translation, we showed that basal
global protein translation is reduced
in VCP-RH-expressing mouse muscle.
MTOR phosphorylates ULK1, inhibiting
autophagosome formation. Diminished
MTOR activity thus leads to an increase
in autophagosome formation. By blocking
autophagosome degradation in vivo with
colchicine we confirmed that VCP-RH
have enhanced autophagosome biogenesis
as compared with control and VCP-WT
mouse muscle.
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cells demonstrated that a potent VCP
inhibitor, N2,N4-dibenzylquinazoline2,4-diamine (DBeQ), decreases both
basal and nutrient-stimulated phosphorylation of MTOR targets similar to
the effects of rapamycin. These findings,
therefore, harmonize the in vivo data.
What are the chances and promises of
restoring MTOR activity in IBMPFD/
ALS? The unexpected observation that
MTOR dysfunction aggravates weakness
and pathology in IBMPFD/ALS led to
the proposition that restoration of MTOR
activity in the setting of this disease may
provide clues to therapeutic strategies.
MTOR signaling requires translocation
of MTOR to an acidic late endosomal
compartment that contains RHEB, and
the integrity of the endo-lysosomal system
is necessary for this process. Inhibition of
VCP activity and IBMPFD/ALS mutant
VCP expression disrupts endo-lysosomal
trafficking resulting in enlarged nonacidic
late endosomes. To this end, we suspected
that aberrant endo-lysosomes may fail to
localize RHEB or redistribute MTOR
upon nutrient stimulation. With this in
mind, we transfected GFP or constitutively active RHEB (caRheb-N153T-Flag)
into U20S cells in the setting of DBeQ
treatment and into stable VCP mutant
cell lines including VCP-E578Q and
VCP-R155H. Although restoration of the
phosphorylation of RPS6 is less robust in
the setting of DBeQ treatment and VCPE578Q, the restoration in VCP-R155H is
comparable to the VCP-WT cells. These
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data, coupled with the fact that RHEB
expression can increase the myofiber size
when transiently expressed, established
an emerging hypothesis that activation
of MTOR by RHEB may be a viable and
commendable therapeutic approach for
IBMPFD/ALS. To further lend credence
to this hypothesis, we demonstrated that
transient expression of the caRheb-N153TFlag plasmid, by electroporation, into
mouse tibialis anterior muscle is capable of
activating MTOR and recovering myofiber size in VCP-RH mice. Thus, our recommendations for future studies toward
obtaining a finer picture of the outcome
of restoring MTOR activity in IBMPFD/
ALS hinge on a closer inspection of prolonged RHEB expression to determine
whether it can abrogate weakness, vacuolation and inclusion body formation in
VCP-IBM mice.
In conclusion, our data, which provide evidence that MTOR signaling is
disrupted in IBMPFD/ALS resulting in
increased autophagosome biogenesis, constitute a major leap forward in our understanding of the pathobiology of IBMPFD.
Notably, chronic rapamycin treatment significantly worsens the degenerative phenotype in VCP-RH mice. Thus, the data
suggest a new role for VCP in autophagy,
specifically, that VCP regulates MTOR
signaling.
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Having established that MTOR signaling is defective in IBMPFD/ALS, we
further inhibited MTOR by treating mice
every other day for 21 d with rapamycin,
a well-established autophagy inducer.
Surprisingly, compared with control and
VCP-WT mice, VCP-RH mice develop
a further decrease in muscle strength,
concomitant with a significant increase
in serum creatine kinase levels as well as
the number of vacuolated and atrophic
fibers in response to rapamycin treatment.
Similarly, autophagic substrates accumulate more in VCP-RH mice following
rapamycin treatment. These findings suggest that chronic inhibition of MTOR,
which results in enhanced autophagosome
biogenesis, significantly worsens the
already existing muscle degenerative phenotype in VCP-RH mice. MTOR activity
is responsive to upstream environmental
cues such as insulin or IGF1, nutrients,
and energy changes. Which of these signaling pathways underlies MTOR dysfunction in the setting of VCP mutations?
To address this question, we showed that
phosphorylation of AKT, a central player
in the insulin signaling pathway, is stimulated by insulin in both VCP-WT and
VCP-RH mice. Furthermore, we found
that activation of AMPK, a master sensor/
gauge for cellular energy, is unaffected in
VCP-RH mice. However, treating mice
with leucine i.p. after overnight starvation
diminishes MTOR activation in VCP-RH
mice compared with VCP-WT mice.
Complementary experiments using U20S

